No Data
Xi'an Global Printing (002799.SZ): Lankai Technology currently has no cooperation with Douyin's taxi business.
On February 6, Gelonghui reported that Xi'an Global Printing (002799.SZ) stated on the investor interaction platform that its subsidiary, Lingkai Technology, is an Internet Plus-Related digital marketing Operation service provider, offering clients technical support, material and creative design production, material operation, placement testing, and performance analysis services, assisting clients in market development and product promotion. Lingkai Technology is a comprehensive service provider for the marketing services brand of ByteDance, the giant engine operation business, a service provider for the giant Qinchuan, and a service provider for Douyin local life services, and currently, there is no cooperation with Douyin's ride-hailing business. Lingkai Technology is currently maintaining friendly cooperation with Amap, mainly serving Amap map services.
Global Printing: 2024 Annual Results Forecast
Xi'an Global Printing (002799.SZ): Expected loss of 32 million yuan to 59 million yuan for the 2024 fiscal year.
On January 24, Gelonghui reported that Xi'an Global Printing (002799.SZ) announced its annual performance forecast for 2024, projecting a net loss attributable to the shareholders of the listed company between 32 million yuan and 59 million yuan. After deducting non-recurring gains and losses, the net loss is expected to be between 35.5 million yuan and 62.5 million yuan, with basic EPS expected to be a loss of 0.10 yuan/share to 0.18 yuan/share. A subsidiary of the company, Horgos Linkai Network Technology Co., Ltd., has overdue accounts receivable from the client Peking Brainstorm Technology Co., Ltd., and based on the principle of prudence, the company is taking measures.
Xi'an Global Printing (002799.SZ): Currently, the company's revenue from overseas business accounts for a relatively small proportion.
Guangzhou Stock Exchange reported on January 17 that Xi'an Global Printing (002799.SZ) stated on an investor interaction platform that the company, as a professional provider of pharmaceutical packaging, is mainly engaged in the research and development, production, and sales of pharmaceutical packaging products, while also offering integrated packaging solutions for customers including project planning, graphic design, structural design, warehouse management, and logistics distribution. Currently, the overseas business revenue accounts for a small proportion, and the company will continue to pay attention to relevant industry and market dynamics, and based on the actual development of the company, will orderly promote overseas pharmaceutical packaging business under the premise of ensuring that risks are controllable.
Xi'an Global Printing (002799.SZ): Focus on the research and development, production, and services of high-end exquisite packaging and related packaging materials for paper products such as Cosmetic, medical instruments, health products, and fast-moving c
On December 18, Gelonghui reported that Xi'an Global Printing (002799.SZ) stated on the investor interactive platform that as a professional pharmaceutical packaging supplier, the company mainly engages in the research and development, production, and sales of pharmaceutical packaging products, and provides clients with integrated packaging solutions including program planning, graphic design, structural design, warehousing management, and Logistics distribution. At the same time, the company focuses on the research and development, production, and services of high-end exquisite paper packaging and related packaging materials for aesthetic cosmetics, medical instruments, health products, fast-moving consumer goods, and other categories.
Xi'an Global Printing (002799.SZ): Has maintained a good cooperative relationship with Eli Lilly and Co and Novo-Nordisk A/S.
Gelonghui reported on December 12 that Xi'an Global Printing (002799.SZ) stated on the investor interaction platform that the company has maintained a good cooperative relationship with Eli Lilly and Co, Novo-Nordisk A/S, and other enterprises. In the future, the company will continue to strengthen market development efforts and expand its customer base.
